一种具有抗癌潜力的新型神胺瘤类比物,向EGFR蛋白:计算和试验室研究
Ibrahim H Eissa1, Reda G Yousef1, Eslam B Elkaeed2
1Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
ACS omega
|April 15, 2024
概括
这项研究引入了T-1-PMPA,一种具有亡性质的新型EGFR抑制剂. T-1-PMPA显示出显著的抗癌作用和作为癌症治疗的化合物的潜力.
科学领域:
- 药用化学 医学化学
- 计算化学的计算化学
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 是癌症治疗的关键标.
- 在癌症治疗中,开发具有增强疗效和亡性质的新型EGFR抑制剂至关重要.
研究的目的:
- 设计和评估一种具有潜在的亡活性的新型EGFR抑制剂T-1-PMPA.
- 使用计算和体外方法探索T-1-PMPA的结合亲和力,抑制潜力和安全性.
主要方法:
- 从神胺中半合成T-1-PMPA.
- 在分析包括ADMET,DFT,分子对接和分子动力学模拟.
- 通过EGFR抑制试验,癌细胞增殖研究,流细胞计和基因表达分析进行体外验证.
主要成果:
- T-1-PMPA证明有效地抑制了EGFRWT和EGFR790m (IC50值:86和561nM). 这是一个很好的结果.
- 显著抑制HepG2和MCF7细胞增殖 (IC50值:3.51和4.13μM),具有良好的选择性指数.
- 通过流式细胞计测证实了亡效应,增加了Casp3/Casp9表达,并调节了TNFα和IL2.
结论:
- T-1-PMPA表现出有希望的抗癌特性,包括强大的EGFR抑制和诱导亡.
- T-1-PMPA代表了一种潜在的化合物,用于开发针对EGFR的新型亡性抗癌药物.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


